Evidence map›Paper›PMID 31584992›Full record

ArticlePloS one2019

Predictors of mortality within the first year of initiating antiretroviral therapy in urban and rural Kenya: A prospective cohort study.

Rachel A Silverman, Grace C John-Stewart, Ingrid A Beck, Ross Milne, Catherine Kiptinness, Christine J McGrath, Barbra A Richardson, Bhavna Chohan, Samah R Sakr, Lisa M Frenkel and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Predictors of All-Cause Mortality Among People With Human Immunodeficiency Virus (HIV) in a Prospective Cohort Study in East Africa and Nigeria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Rachel A SilvermanDepartment of Epidemiology, University of Washington, Seattle, Washington, United States of America.ORCID 0000-0003-3082-9664
Grace C John-StewartDepartment of Epidemiology, University of Washington, Seattle, Washington, United States of America.
Ingrid A BeckSeattle Children's Research Institute, Seattle, Washington, United States of America.
Ross MilneSeattle Children's Research Institute, Seattle, Washington, United States of America.
Catherine KiptinnessDepartment of Global Health, University of Washington, Seattle, Washington, United States of America.
Christine J McGrathDepartment of Global Health, University of Washington, Seattle, Washington, United States of America.
Barbra A RichardsonDepartment of Global Health, University of Washington, Seattle, Washington, United States of America.
Bhavna ChohanDepartment of Global Health, University of Washington, Seattle, Washington, United States of America.
Samah R SakrCoptic Hospital, Nairobi, Kenya.
Lisa M FrenkelDepartment of Global Health, University of Washington, Seattle, Washington, United States of America.
Michael H ChungDepartment of Epidemiology, University of Washington, Seattle, Washington, United States of America.
University of Washington · USNairobi Hospital · KE

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
Drug-resistance testing in Kenya to improve ART suppression of HIV replicationR01AI100037 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI FRENKEL, LISA M · 2012 to 2014
$3.1M
Reservoirs of drug-resistant HIV-1R01AI058723 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI FRENKEL, LISA M · 2005 to 2009
$2.0M
NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI058723NIAID NIH HHS R01 AI100037PEPFAR
6 · The paper itself

Abstract

introductionDespite increased treatment availability, HIV-infected individuals continue to start antiretroviral therapy (ART) late in disease progression, increasing early mortality risk. MATERIALS AND

methodsNested prospective cohort study within a randomized clinical trial of adult patients initiating ART at clinics in urban Nairobi and rural Maseno, Kenya, between 2013-2014. We estimated mortality incidence rates following ART initiation and used Cox proportional hazards regression to identify predictors of mortality within 12 months of ART initiation. Analyses were stratified by clinic site to examine differences in mortality correlates and risk by location.

resultsAmong 811 participants initiated on ART, the mortality incidence rate within a year of initiating ART was 7.44 per 100 person-years (95% CI 5.71, 9.69). Among 207 Maseno and 612 Nairobi participants initiated on ART, the mortality incidence rates (per 100 person-years) were 12.78 (95% CI 8.49, 19.23) and 5.72 (95% CI 4.05, 8.09). Maseno had a 2.20-fold greater risk of mortality than Nairobi (95% CI 1.29, 3.76; P = 0.004). This association remained [adjusted hazard ratio (HR) = 2.09 (95% CI 1.17, 3.74); P = 0.013] when adjusting for age, gender, education, pre-treatment drug resistance (PDR), and CD4 count, but not when adjusting for BMI. In unadjusted analyses, other predictors (P<0.05) of mortality included male gender (HR = 1.74), age (HR = 1.04 for 1-year increase), fewer years of education (HR = 0.92 for 1-year increase), unemployment (HR = 1.89), low body mass index (BMI<18.5 m/kg2; HR = 4.99), CD4 count <100 (HR = 11.67) and 100-199 (HR = 3.40) vs. 200-350 cells/μL, and pre-treatment drug resistance (PDR; HR = 2.49). The increased mortality risk associated with older age, males, and greater education remained when adjusted for location, age, education and PDR, but not when adjusted for BMI and CD4 count. PDR remained associated with increased mortality risk when adjusted for location, age, gender, education, and BMI, but not when adjusted for CD4 count. CD4 and BMI associations with increased mortality risk persisted in multivariable analyses. Despite similar baseline CD4 counts across locations, mortality risk associated with low CD4 count, low BMI, and PDR was greater in Maseno than Nairobi in stratified analyses.

conclusionsHigh short-term post-ART mortality was observed, partially due to low CD4 count and BMI at presentation, especially in the rural setting. Male gender, older age, and markers of lower socioeconomic status were also associated with greater mortality risk. Engaging patients earlier in HIV infection remains critical. PDR may influence short-term mortality and further studies to optimize management will be important in settings with increasing PDR.

Indexed as

Rural HealthUrban HealthAntiretroviral Therapy, Highly ActiveHealth Services AccessibilityHIV InfectionsHumansIncidenceKaplan-Meier EstimateKenyaMortalityProportional Hazards ModelsSocioeconomic FactorsTime-to-Treatment

Identifiers

PMID31584992
PMCPMC6777822
OpenAlexW2978499523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.